News and Trends 18 Oct 2017 Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data OncoDNA is gathering prestigious oncology centers to take part in Moncodaneum, an international project to bring precision medicine to cancer patients. The Belgian biotech OncoDNA has announced that it will be collaborating with the Strasbourg University Hospital, France, and the Oncology Center of Bydgoszcz, Poland, in the advancement of precision medicine for cancer. The two […] October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Biotech Crosses the Channel to Raise €9.7M for its Diagnostics Tools Novacyt will use the money raised on the AIM market, London, to expand its manufacturing capacity and continue research looking into new techniques. Novacyt specializes in diagnostic tools for a number of indications, including cancer and infectious diseases. Today, it has announced that it has raised €9.7M by placing stocks on the London-based Alternative Investment Market (AIM). […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2017 Swedish Human Cell Atlas gets the Support of Chan & Zuckerberg The Human Cell Atlas will map all of the cells in the body, and the Chan Zuckerberg Initiative has given a grant to Swedish researchers to join the project. Mark Zuckerberg and his wife, Priscilla Chan, founded the Chan Zuckerberg Initiative to provide resources for projects, including biomedical research. The Initiative supports the Human Cell Atlas, an exciting […] October 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2017 Genfit Gets €180M Cash Injection to Bring its Pipeline to Market Elafibranor, Genfit’s lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and therapeutics for metabolic and inflammatory diseases. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH) – an inflammatory disease of the liver. The company has raised €180M by selling bonds […] October 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Biotech Power-Couple Sees Positive Phase II Results For Inflammatory Disease Drug Regeneron and Sanofi’s drug, dupilumab, has met primary and secondary endpoints for the treatment of eosinophilic esophagitis. The biotech-biopharma giants have announced that their candidate, Dupilumab, demonstrated good efficacy during a Phase II trial. The drug is designed for use against eosinophilic esophagitis, a nasty inflammatory disease of the esophagus that makes it difficult to swallow. […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research. The Swiss firm BC Platforms has built a platform to facilitate access to and analysis of large volumes of genomic and clinical data. Since September, the company has been collaborating with Microsoft, […] October 16, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 French Biotech Lifted by €7M Series A to Develop New Antibiotics Antabio has taken a step towards tackling antibiotic resistance by securing a €7.3M Series A. The funding will accelerate the company’s candidate through a Phase I clinical trial. Antabio is a French biopharma that focuses on one of the world’s biggest crises – antibiotic resistance. The company has raised €7.3M in Series A of fundraising, which it will use to […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […] October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Interview: On the Future of iPS Cells and why Partnering is so Important in this Field In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […] October 16, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 New Stem Cells Could Take Cell Research and Therapies to the Next Level British researchers have created a new type of stem cell in mice. It has even greater potential than current cell lines in research and in the clinic. Stem cells have huge potential in research and therapeutics and overcome the limitations of current cell lines – embryonic and induced pluripotent stem cells. Findings published in Nature report that researchers at […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Why Might Biotechs Lose Easy Access to Scientific Papers? Five publishers have ordered ResearchGate to take down articles. Researchers might continue to get around the paywall with Sci-Hub and other initiatives. ResearchGate, described as ‘Facebook for scientists’, has over 13 million members. It has raised more than $80M (€68M) from investors including Bill Gates and the Wellcome Trust. But, five scientific publishers including Elsevier and Wiley have clubbed […] October 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Sanofi Invests €170M in French Facilities to Expand Flu Vaccine Supply Sanofi Pasteur will expand its main vaccine manufacturing site to increase distribution of its quadrivalent flu vaccine VaxigripTetra around the world. Sanofi will invest €170M in expanding its vaccine production facilities in Val de Reuil, France, which also hosts its global vaccine distribution center, from which it currently ships 900 million vaccine doses a year. The company plans to complete the expansion by […] October 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email